InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-32.7%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Coiante Scott M, Chief Financial Officer. Officer active across 2 companies, notably Aprea Therapeutics, Inc.. Cumulatively, 8 disclosures have been published. History available since 25 August 2021. The latest transaction was disclosed on 26 August 2024 (Disposition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations8 total
15,000 shares@ US$1.52100.0% of flowCommon StockSEC:0001104659-24-092946:0
20,000 shares0Common StockSEC:0001104659-23-106855:0
60,800 shares0Common StockSEC:0001104659-22-084760:0
35,284 shares@ US$0.8050.44% mcap26.3% of flowCommon StockSEC:0001104659-22-069009:0
42,900 shares0Common StockSEC:0001104659-22-033391:0
14,817 shares@ US$1.740.39% mcap22.9% of flowCommon StockSEC:0001104659-22-028760:0
7,534 shares@ US$3.9825.4% of flowCommon StockSEC:0001104659-21-110596
7,534 shares@ US$3.980.43% mcap25.4% of flowCommon StockSEC:0001104659-21-110596:0
8 of 8 declarations
About Coiante Scott M
Scott M. Coiante is the Chief Financial Officer and Senior Vice President of Aprea Therapeutics, Inc. He is responsible for the financial management of the company, including budgeting, risk management, and financial reporting. His role is crucial in ensuring the financial health and sustainability of the organization.
